President Trump on Tuesday nominated Dr. Heidi Overton, his deputy assistant for domestic policy, to serve as the next commissioner of the Food and Drug Administration, calling her a "ROCKSTAR" who will push the administration's health agenda forward alongside HHS Secretary Robert F. Kennedy Jr. and Dr. Oz.
Overton, a board-certified physician in public health and general preventive medicine, holds a Ph.D. in clinical investigations from Johns Hopkins University. She previously served as a White House Fellow during Trump's first term and spent four years leading health policy at the America First Policy Institute before returning to the White House in 2025.
Trump framed the pick squarely around his "Make America Healthy Again" priorities, linking Overton's role to faster drug approvals, lower prices, and sweeping clinical trial reforms. In a statement first reported by Newsmax, the president made clear he views the FDA post as central to keeping the United States at the front of global biomedical competition.
"We need her leadership at the FDA now to ensure that the U.S. remains the WORLD LEADER for Scientific Discovery and CURES."
Trump also emphasized the breadth of her portfolio inside the West Wing, noting that Overton regularly briefs him on health issues and has worked hand-in-hand with Kennedy and Dr. Oz on policy rollouts. Just The News reported that the nomination is directly tied to supporting Kennedy's initiatives, including revisiting federal vaccine schedules and scrutinizing food additives.
In a second statement, Trump laid out what he expects from Overton at the agency's helm.
"Dr. Heidi will work with Secretary Kennedy and Dr. Oz to RAPIDLY deliver on my priorities of FASTER Cures, INCREASED American Innovation, MAJOR Clinical Trial Reforms, LOWER Drug Prices, and even more MAHA WINS!"
Overton's nomination carries weight beyond drug approvals and food safety. The FDA regulates mifepristone, one of two drugs used in chemical abortions, and Overton has a well-documented record of opposition to abortion access.
In a February 2023 policy brief, she wrote bluntly about her position. Fox News reported the relevant passage:
"Abortion is corrosive to children, women, and society broadly because it devalues and extinguishes innocent human life."
That language matters because the FDA commissioner wields direct regulatory authority over mifepristone's availability, prescribing rules, and distribution channels. Anti-abortion organizations moved quickly to endorse the pick. Lila Rose, head of Live Action, called Overton's nomination "a chance to restore trust and put health over politics," as the Washington Examiner reported.
Pro-life groups expect Overton to tighten restrictions on the abortion pill if confirmed. For conservatives who have long argued that the FDA expanded mifepristone access without adequate safety review, the nomination signals that the issue will get a second look at the highest level of the agency.
Overton would replace Dr. Marty Makary, the former FDA commissioner who resigned in May after clashing with administration critics. Fox News reported that the departure followed friction over policy direction, while the Washington Examiner characterized it as Makary being "ousted" after a dispute with Trump over flavored vaping products.
The three-month vacancy has left the agency without a Senate-confirmed leader during a period of active public health challenges. Fox News noted that the FDA is currently managing a multistate Cyclospora outbreak, adding operational urgency to the confirmation timeline.
Overton's path from the America First Policy Institute to the Domestic Policy Council to an agency nomination follows a pattern the Trump White House has used in its second term: elevating loyalists with policy credentials who already operate inside the administration's orbit. Her time at AFPI from 2021 to 2025 gave her a platform to shape conservative health policy outside government, and her current West Wing role gave her direct access to the president on day-to-day health decisions.
The FDA commissioner requires Senate confirmation, and Overton's hearing will almost certainly center on three flashpoints: her stance on mifepristone, her role in the administration's executive order overhauling childhood vaccine recommendations, and her vision for clinical trial reform.
Democrats are likely to press hard on the abortion pill question, given her 2023 policy brief. Republicans will probably use the hearing to highlight what they see as overdue accountability at an agency that conservatives have criticized for regulatory overreach and sluggish drug approvals.
Overton's medical credentials and Johns Hopkins doctorate give her a stronger academic profile than some previous nominees, but her confirmation fight will turn less on her CV than on the policy battles the FDA now sits at the center of.
The FDA touches nearly every corner of American life: the safety of the food supply, the speed at which new drugs reach patients, the rules governing vaccines, and the legal status of abortion medication. Trump has made clear he wants a commissioner who will not slow-walk his agenda or buckle under political pressure from the left.
Overton's nomination tells conservatives that the White House views the FDA not as a technocratic backwater but as a front line in the broader fight over health freedom, drug pricing, and the protection of unborn life. Whether the Senate agrees will determine how far that fight advances.
When the agency that regulates your medicine cabinet, your grocery store, and the most contested drug in American politics needs a new leader, the pick is never just about science. It is about who gets to decide what "safe" means.
